Table 1. Clinical characteristics of study cohorts.

Characteristic
Localized prostate cancer cohort	n (%)	Pa
Patients, n	458
Age at diagnosis		0.303
Median, y (IQR)	66 (61–70)
≤65	211 (46.1)
>65	247 (53.9)
PSA at diagnosis		<0.001
Median, ng/mL (IQR)	11.1 (7.1–17.5)
≤10	197 (44.9)
>10	242 (55.1)
Pathologic Gleason score, n (%)		<0.001
≤6	160 (35.3)
>6	293 (64.7)
Pathologic stage, n (%)		<0.001
T1/T2	303 (67.2)
T3/T4/N1	148 (32.8)
BCR	184 (40.2)
Median follow-up timeb, mo (95% CI)	54 (50–58)
Advanced prostate cancer cohort	n (%)	Pc
Patients, n	504
Age at diagnosis		0.016
Median, y (IQR)	73 (66–79)
≤72	250 (49.6)
>72	254 (50.4)
PSA at ADT initiation		0.022
Median, ng/mL (IQR)	33.8 (9.3–133.3)
≤34	253 (51.6)
>34	237 (48.4)
Biopsy Gleason score at diagnosis, n (%)		<0.001
≤7	312 (63.4)
>7	180 (36.6)
Clinical stage at diagnosis, n (%)		<0.001
M0	308 (61.4)
M1	194 (38.6)
PSA nadir		<0.001
Median, ng/mL (IQR)	0.14 (0.01–1.06)
<0.2	275 (54.8)
≥0.2	227 (45.2)
Time to PSA nadir		<0.001
Median, mo (IQR)	10 (5–20)
<10	236 (47.0)
≥10	266 (53.0)
Treatment modality		0.002
ADT as primary treatment	254 (50.5)
ADT for post RP PSA failure	73 (14.5)
ADT for post RT PSA failure	12 (2.4)
Neoadjuvant/adjuvant ADT with RT	122 (24.3)
Others	42 (8.3)
Disease progression	457 (90.7)
Median follow-up timeb, mo (95% CI)	87 (79–95)

Abbreviations: IQR, interquartile range; PSA, prostate-specific antigen; BCR, biochemical recurrence; CI, confidence interval; ADT, androgen deprivation therapy; RP, radical prostatectomy; RT, radiation therapy.

^aP value was calculated by the log-rank test for BCR in localized prostate cancer patients.

^bMedian follow-up time and 95% CIs were estimated with the reverse Kaplan-Meier method.

^cP value was calculated by the log-rank test for disease progression in advanced prostate cancer patients.